Page last updated: 2024-08-25

bexarotene and Exanthem

bexarotene has been researched along with Exanthem in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A	1
Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S	1
Bolejack, V; Crowley, J; Ekstrand, B; Ghalie, R; Govindan, R; Jaunakais, D; Kennedy, P; Sandler, A; Schwartzberg, L; Williams, C	1

Reviews

1 review(s) available for bexarotene and Exanthem

Article	Year
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. American journal of hematology, 2008, Volume: 83, Issue:9 Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2008

Article

Year

CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.

American journal of hematology, 2008, Volume: 83, Issue:9

Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine

2008

Trials

2 trial(s) available for bexarotene and Exanthem

Article	Year
Bexarotene and erlotinib for aerodigestive tract cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2005
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Capsules; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Survival Analysis; Tetrahydronaphthalenes	2006

Article

Year

Bexarotene and erlotinib for aerodigestive tract cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured

2005

Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Capsules; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Survival Analysis; Tetrahydronaphthalenes

2006